RecruitingDrug trialDose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or LymphomasThis is a phase 1/2, multicenter, dose-finding and dose expansion study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas.